Table 2.
Patient Demographics of All Subjects Combined ABBY and BLAZE Studies
| Characteristic | 15mg/kg Crenezumab IV Every 4 Weeks, n = 198 | 300 mg Crenezumab SC Every 2 Weeks, n = 148 | Placebo, n = 176 |
|---|---|---|---|
| Age, yr (SD) | 71 (6.9) | 70.4 (7.1) | 70 (7.2) |
| Sex, F (%) | 106 (53.5%) | 80 (54.1%) | 92 (52.3%) |
| MMSE mean score (SD) | 21.7 (2.7) | 21.7 (2.7) | 21.5 (2.5) |
| MMSE score 22–26, n (%) | 101 (51%) | 70 (47.3%) | 82 (46.6%) |
| APOE ε4 carriers, n (%) | 139 (70.2%) | 100 (67.6%) | 124 (70.5%) |
| ADAS‐Cog12 mean score (SD) | 29.3 (9.3) | 28.4 (8.7) | 28.5 (8.8) |
| CDR‐SB mean score (SD) | 4.6 (2.1) | 4.6 (1.9) | 4.6 (2.1) |
| ADCS‐ADL mean score (SD) | 64.2 (10.4) | 64.6 (9.5) | 64.9 (10.1) |
ADAS‐Cog12 = Alzheimer's Disease Assessment Scale–Cognitive Subscale; ADCS‐ADL = Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory; CDR‐SB = Clinical Dementia Rating–Sum of Boxes; F = female; IV = intravenous; MMSE = Mini‐Mental State Examination; SC = subcutaneous; SD = standard deviation.